SYRE Stock Analysis: Buy, Sell, or Hold?
SYRE - Spyre Therapeutics, Inc. Common Stock
$68.63
-3.27 (-4.55%)
▼
5d:
-3.7%
30d:
+45.06%
90d:
+105.73%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 14, 2026
14d
Get Alerted When SYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SYRE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SYRE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SYRE is currently trading at $68.63, which is considered slightly high relative to its 30-day fair value range of $46.84 to $69.25.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $64.60, while resistance sits at $74.84. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: SYRE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.13 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $64.60, while resistance sits at $74.84. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: SYRE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.13 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$46.84 -
$69.25
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 31.3% below Wall St target ($90.13)
Trading Range Analysis
30-Day Trading Range
$46.84 -
$69.25
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$64.60
Resistance Level
$74.84
Current Trend
Strong Uptrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.72
Wall Street Target
$90.13
(+31.3%)
Earnings Growth (YoY)
-99.7%
Share & Embed Analysis
Last updated: April 29, 2026 7:43 AM ET
Data refreshes hourly during market hours. Next update: 8:43 AM
Data refreshes hourly during market hours. Next update: 8:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Cameron Turtle
SELL
15000 shares
2026-04-01
Scott L Burrows
SELL
7500 shares
2026-04-01
Sheldon Sloan
SELL
7958 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$107 | 50 HOLD |
